PEP-005: Treatment of actinic keratoses acute myeloid leukemia therapy treatment of basal cell carcinoma protein kinase C activator

Drugs of the Future

Volumn 30, Issue 10, 2005, Pages 1003-1005

  Hampson, P ^a   Wang, K ^a   Lord, J M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISTRATENE A; BRYOSTATIN 1; CASPASE 3; CD34 ANTIGEN; DIACYLGLYCEROL; DITERPENE; ESTER DERIVATIVE; FAS ANTIGEN; HYDROGEN PEROXIDE; INGENOL 3 ANGELATE; ISOENZYME; PEP 005; PHORBOL ESTER; PHORBOL MYRISTATE; POLYPHOSPHOINOSITIDE; PROTEIN KINASE C; PROTEIN KINASE C ACTIVATOR; ROTTLERIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BASAL CELL CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; EUPHORBIA; HUMAN; LD 50; LETHARGY; LEUKEMIA CELL LINE; MAXIMUM TOLERATED DOSE; MIOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RESPIRATORY FAILURE; SKIN BIOPSY; SKIN CANCER; SUBCUTANEOUS TISSUE TUMOR; TACHYPNEA; VERRUCA VULGARIS; WEIGHT REDUCTION;

EID: 30744439050     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.10.942816     Document Type: Article

References (12)

1. Dekker, L.V., Parker, PJ. Protein kinase C-A question of specificity. Trends Biochem Sci 1994, 19: 73-7.
2. Deacon, E.M., Pongracz, J., Griffiths, G., Lord, J.M. PKC isoenzymes: Differential involvement in apoptosis and differentiation. J Clin Pathol Mol Pathol 1997, 50: 124-31.
3. Gschwendt, M. Protein kinase Cδ. Eur J Biochem 1999, 259: 555-64.
4. Cross, T.G., Griffiths, G., Deacon, E., Sallis, R., Gough, M., Watters, D., Lord, J.M. PKC-δ is an apoptotic lamin kinase. Oncogene 2000, 19: 2331-7.
5. Emoto, Y., Kisaki, H., Moanome, Y., Kharband, S., Kufe, D. Activation of protein kinase Cδ human myeloid leukaemia cells treated with 1-β-D-arabinofuranosylcytosine. Blood 1996, 87: 1990-6.
6. Ghayur, T., Hugunun, M., Talanian, R.V., Ratnofsky, S., Quinlan, C., Emoto, Y., Pandey, P., Wong, W., Kufe, D. Proteolytic activation of protein kinase Co by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med 1996, 184: 2399-404.
7. Man, Z.T., Zhu, X.X., Yang, R.Y., Sun, J.Z., Tian, G.F. et al. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: Preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci USA 1998, 95: 5357-61.
8. Clamp, A., Jayson, G.C. The clinical development of the bryostatins. Anti-Cancer Drugs 2002, 13: 673-83.
9. Weedon, D., Chick, J. Home treatment of basal cell carcinoma. Med J Aust 1986, 1: 928.
10. Ogbourne, S.M., Suhrbier, A., Jones, B., Cozzi, S.J., Boyle, G.M. et al. Antitumor activity of 3-ingenyl angelate: Plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004, 64: 2833-9.
11. Hampson, P., Chahal, H., Khanim, F., Hayden, R., Mulder, A., Assi, L.K., Bunce, C.M., Lord, J.M. PEP005, a selective small molecule activator of protein kinase C, has potent anti-leukemic activity mediated via the delta isoform of PKC. Blood 2005, 106: 1362-8.
12. ClinicalTrials.gov. NCT00108121.